Chimerix CMRX 深 沪
等待开盘 04-01 09:30:00 美东时间
8.54
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.54
- 总市值 8.01亿
- 52周最高 8.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.75
- 委 比 0.00%
- 总股本 9380.38万
- 历史最高 58.04
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.75
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches
Earnings Call Insights: Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Management View Renée Galá, President and CEO, stated, "Jazz had an exceptional year in 2025, representing our 21st consecutive year of ...
02-25 13:58
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNe...
01-09 05:05
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma公司宣布前Chimerix资深商业领导人Michael Grabow出任首席商务官，领导NXC-201在美国的上市及商业化进程。NXC-201针对复发性/难治性AL淀粉样变，此类疾病目前无FDA批准疗法。Michael Grabow拥有25年生物制药商业化经验，曾成功领导孤儿药MODEYSO®的上市。NXC-201获FDA授予再生医学先进疗法（RMAT）和罕见病药物认证（ODD），旨在解决该罕见病高未满足需求。
2025-11-12 13:45
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an over...
2025-08-21 04:15
Jazz Pharmaceuticals Reports Q2 2025 Revenues of $1.05 Billion and Significant Non-GAAP Adjusted Net Loss of $504.8 Million, EPS Drops to $(8.25)
Jazz Pharmaceuticals plc has announced its financial results for the second quarter of 2025, reporting total revenues of $1.05 billion. This figure includes a 13% year-over-year increase in Xywav® rev...
2025-08-06 04:11
Chimerix Terminates Loan and Delists from Nasdaq
The latest announcement is out from Chimerix ( ($CMRX) ). On April 21, 2025, Ch...
2025-04-22 04:52
Jazz Pharmaceuticals Completes Acquisition of Chimerix
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewsw...
2025-04-22 04:05
Chimerix Reports 2024 Losses Amid Acquisition News
Chimerix ( ($CMRX) ) has released its Q4 earnings. Here is a breakdown of the i...
2025-03-25 11:52
Chimerix GAAP EPS of -$0.25 beats by $0.01, revenue of $0.06M misses by $0.25M
Chimerix press release (NASDAQ:CMRX): Q4 GAAP EPS of -$0.25 beats by $0.01. Revenue of $57K (vs. $4K Y/Y) misses by $0.25M. Chimerix’s balance sheet at December 31, 2024 included $140.1 million of cap...
2025-03-21 18:07
Chimerix Q4 2024 GAAP EPS $(0.25) Beats $(0.26) Estimate, Sales $57.00K Miss $75.00K Estimate
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 25 percent decrease over losses of $(0.20) per share from the same
2025-03-21 18:04
